HIV clinic-based extended-release naltrexone versus treatment as usual for people with HIV and opioid use disorder: a non-blinded, randomized non-inferiority trial.
Philip Todd KorthuisRyan R CookPaula J LumElizabeth Needham WaddellHansel TookesPamela Vergara-RodriguezLynn E KunkelGregory M LucasAllan E RodriguezSarann BielavitzLaura C FanucchiKim A HoffmanKen BachrachElizabeth H PayneJulia A CollinsAbigail MatthewsNeal OdenPetra JacobsEve JelstromJames L SorensenDennis McCartyPublished in: Addiction (Abingdon, England) (2022)
A randomized controlled trial found supportive, but not conclusive, evidence that human immunodeficiency virus clinic-based extended-release naltrexone is not inferior to treatment as usual for facilitating human immunodeficiency virus viral suppression. Participants who initiated extended-release naltrexone used fewer opioids than those who received treatment as usual.